Ginkgo Bioworks Holdings’ Revenue by Segment (2020-2023)

This statistic highlights Ginkgo Bioworks Holdings’ Revenue by Segment, split between Crop Nutrient Blends, Other, Performance Products, Phosphate Crop Nutrients, Phosphate Rock, Potash Crop Nutrients, and Specialty Products, reported quarterly from Q3 2020 onwards

Ginkgo Bioworks Holdings’ Revenue by Segment

(All the values are in USD except percentage)

In the realm of biotechnology and innovation, Ginkgo Bioworks Holdings has established itself as a trailblazing leader. The Q2 2023 revenue breakdown by segment offers a comprehensive insight into the company’s diverse revenue streams, highlighting its pivotal role in advancing healthcare solutions. Let’s delve into the data to decipher the significance of each segment and its implications for Ginkgo Bioworks Holdings’ continued success.

Biosecurity Revenue – Product:

Biosecurity takes centre stage, contributing 14.5% of Ginkgo Bioworks Holdings’ Q2 2023 revenue, totalling $1,166,600. This category’s prominence underscores Genentech’s commitment to developing products that actively safeguard health and well-being. These products might include pharmaceuticals, vaccines, or treatments designed to combat various health threats, reflecting the company’s dedication to preventive healthcare solutions.

Biosecurity Revenue – Service:

The “Service” arm of Biosecurity shines as a powerhouse, contributing a remarkable 43.3% of revenue, equivalent to $3,494,000. This segment likely encompasses services such as diagnostics, consultations, or medical support, highlighting Ginkgo Bioworks Holdings’ holistic approach to healthcare. The substantial revenue from this category underscores the company’s role in providing not just products but comprehensive health-oriented services.

Foundry Revenue:

Foundry revenue stands strong at 42.2%, amounting to $3,409,600. This category represents Ginkgo Bioworks Holdings’ prowess in the laboratory, where scientific innovation is forged. It likely includes revenue from research collaborations, licensing, or partnerships, symbolizing the company’s commitment to pushing the boundaries of scientific discovery and advancing medical breakthroughs.

In conclusion, Ginkgo Bioworks Holdings’ Q2 2023 segment revenue breakdown reflects a company deeply rooted in its mission to advance healthcare. The combination of product-based and service-oriented Biosecurity revenue showcases a commitment to holistic health solutions. Simultaneously, the Foundry revenue category speaks to the company’s dedication to research, innovation, and forging alliances that drive transformative medical progress. As healthcare continues to evolve, Ginkgo Bioworks Holdings’ diversified revenue streams position it to remain at the forefront of innovation, benefiting patients and shaping the future of medicine.

About Ginkgo Bioworks Holdings:

Ginkgo Bioworks Holdings, founded in 1976, stands as a pioneering force in the biotechnology industry. Acquired by the Roche Group in 2009, it retained its individual identity while benefiting from Roche’s resources. Famed for innovative pharmaceuticals, Ginkgo Bioworks Holdings harnessed genetic engineering to create revolutionary treatments. Notably, it developed the first recombinant human insulin and growth hormone. With a strong focus on research and development, the company specializes in biologic medicines derived from living organisms, often targeting specific molecular pathways in diseases. Its oncology contributions are noteworthy, transforming cancer treatment and patient outcomes. Ginkgo Bioworks Holdings’ commitment extends to corporate social responsibility, supporting healthcare access and community development. As a leader in biotech, Ginkgo Bioworks Holdings’ contributions have redefined medicine and healthcare, exemplifying the potential of science-driven innovations to improve lives.

Did you like Ginkgo Bioworks Holdings’ Revenue by Segment statistic?

Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.

You can get started here.